Now Reading: Aurobindo launches Adquey, enters US dermatology market
-
01
Aurobindo launches Adquey, enters US dermatology market
Aurobindo Pharma subsidiary Acrotech Biopharma has launched Adquey (difamilast) in the US, the company's first novel dermatology drug. The non-steroidal topical ointment treats mild-to-moderate atopic dermatitis in adults and children aged two and above.
The drug, licensed from Japan's Otsuka Pharmaceutical, competes with Arcutis Biotherapeutics' Zoryve and Pfizer's Eucrisa in a market estimated at about $1.3 billion for the 12 months ending July 2026. Brokerage Nuvama expects peak sales of around $300 million. Acrotech has set up a dedicated dermatology business unit for the launch. US sales account for about 40 per cent of Aurobindo's revenue.
Indian Opinion Analysis
The Economic Times and The Hindu both report the same core facts: Acrotech's launch of Adquey, the market size of $1.3 billion, and the licensing deal with Otsuka. The Economic Times adds business context absent from The Hindu: Nuvama's peak sales estimate of $300 million, the product's competition with Zoryve and Eucrisa, the company's FY27 revenue guidance of $2 billion, and its share price rise of over 1.2 per cent. The Hindu sticks to a shorter, straight-news summary of the launch and the new dermatology unit. The coverage is uniform in substance, The Economic Times simply provides a fuller commercial and market framing.
Coverage: 2 sources, 2 neutral
Sources (2): economictimes.indiatimes.com (neutral report), thehindu.com (neutral report)
This brief was synthesised by AI from the 2 sources linked above, so one read covers every framing they carry. Methodology and corrections.
